Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide.

Caroli A, Antiga L, Cafaro M, Fasolini G, Remuzzi A, Remuzzi G, Ruggenenti P

Clinical journal of the American Society of Nephrology : CJASN25 Feb 2010Cited by 108 (Europe PMC)

PMID20185596PMCIDPMC2863977DOI10.2215/cjn.05380709PepBankPUB-20185596

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with ADPKD, liver volume changed by -71 ± 57 ml with octreotide versus +14 ± 85 ml with placebo.
In plain wordsIn patients with ADPKD, octreotide reduced liver volume more than placebo.
Peptide
Octreotide
Outcome
DecreaseLiver volume change versus placebo
Study
n = 12
Comparator
placebo period
Analysis
Secondary
Outcome group
Liver fat and liver function · Liver
Studied dose
40 mg every 28 days · 6 monthsAs given in this study (human).
Measurements
Liver volume change on octreotide
−71 ml
mean; +/- 57; crossover octreotide period
Liver volume change on placebo
14 ml
mean; +/- 85; crossover placebo period
Source sentences
Summary
Changes in liver volumes were significantly different between the two treatment periods (-71 +/- 57 ml versus +14 +/- 85 ml).
2 context sentences(design, population, supporting numbers)
Summary · context
In a prospective, randomized, double-blind, crossover study, 6 months of octreotide (40 mg every 28 days) therapy limited kidney volume growth more effectively than placebo in 12 patients with ADPKD.
Summary · context
In this secondary, post hoc analysis of the above study, octreotide-induced changes in liver volumes compared with placebo and the relationship between concomitant changes in liver and kidney volumes were evaluated.
Report a problemFND-2018559602
02HumanRandomized controlled trialEfficacy outcome
In patients with ADPKD, octreotide reduced liver volume growth by a net 85 ± 103 ml versus placebo.
In plain wordsIn patients with ADPKD, octreotide reduced liver volume growth versus placebo.
Peptide
Octreotide
Outcome
DecreaseNet liver volume growth reduction
Study
n = 12
Comparator
placebo
Analysis
Secondary
Outcome group
Liver fat and liver function · Liver
Studied dose
40 mg every 28 days · 6 monthsAs given in this study (human).
Measurements
Net liver volume growth reduction, octreotide versus placebo
−85 ml
mean; +/- 103
Source sentences
Summary
Liver and kidney volume changes significantly differed with both treatments (octreotide: -71 +/- 57 ml versus +71 +/- 107; placebo: +14 +/- 85 ml versus +162 +/- 114), but net reductions in liver (-85 +/- 103 ml) and kidney (-91 +/- 125 ml) volume growth on octreotide versus placebo were similar.
2 context sentences(design, population, supporting numbers)
Summary · context
In a prospective, randomized, double-blind, crossover study, 6 months of octreotide (40 mg every 28 days) therapy limited kidney volume growth more effectively than placebo in 12 patients with ADPKD.
Summary · context
In this secondary, post hoc analysis of the above study, octreotide-induced changes in liver volumes compared with placebo and the relationship between concomitant changes in liver and kidney volumes were evaluated.
Report a problemFND-2018559606
03HumanRandomized controlled trialEfficacy outcome
In patients with ADPKD, octreotide reduced kidney volume growth by a net 91 ± 125 ml versus placebo.
In plain wordsIn patients with ADPKD, octreotide reduced kidney volume growth versus placebo.
Peptide
Octreotide
Outcome
DecreaseNet kidney volume growth reduction
Study
n = 12
Comparator
placebo
Analysis
Secondary
Outcome group
Kidney function · Kidney and urinary
Studied dose
40 mg every 28 days · 6 monthsAs given in this study (human).
Measurements
Net kidney volume growth reduction, octreotide versus placebo
−91 ml
mean; +/- 125
Source sentences
Summary
Liver and kidney volume changes significantly differed with both treatments (octreotide: -71 +/- 57 ml versus +71 +/- 107; placebo: +14 +/- 85 ml versus +162 +/- 114), but net reductions in liver (-85 +/- 103 ml) and kidney (-91 +/- 125 ml) volume growth on octreotide versus placebo were similar.
2 context sentences(design, population, supporting numbers)
Summary · context
In a prospective, randomized, double-blind, crossover study, 6 months of octreotide (40 mg every 28 days) therapy limited kidney volume growth more effectively than placebo in 12 patients with ADPKD.
Summary · context
In this secondary, post hoc analysis of the above study, octreotide-induced changes in liver volumes compared with placebo and the relationship between concomitant changes in liver and kidney volumes were evaluated.
Report a problemFND-2018559607
04HumanNon-randomized trialEfficacy outcome
In patients with ADPKD, liver volume decreased significantly from 1595 ± 478 to 1524 ± 453 ml during octreotide treatment.
In plain wordsIn patients with ADPKD, liver volume decreased during octreotide treatment compared with baseline.
Peptide
Octreotide
Outcome
DecreaseLiver volume within octreotide period
Study
n = 12
Comparator
baseline
Analysis
Secondary
Outcome group
Liver fat and liver function · Liver
Studied dose
40 mg every 28 days · 6 monthsAs given in this study (human).
Measurements
Liver volume before octreotide
1595 ml
mean; +/- 478
Liver volume on octreotide
1524 ml
mean; +/- 453
Source sentences
Summary
Liver volumes significantly decreased from 1595 +/- 478 ml to 1524 +/- 453 ml with octreotide whereas they did not appreciably change with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
In a prospective, randomized, double-blind, crossover study, 6 months of octreotide (40 mg every 28 days) therapy limited kidney volume growth more effectively than placebo in 12 patients with ADPKD.
Summary · context
In this secondary, post hoc analysis of the above study, octreotide-induced changes in liver volumes compared with placebo and the relationship between concomitant changes in liver and kidney volumes were evaluated.
Report a problemFND-2018559601
05HumanNon-randomized trialEfficacy outcome
In patients with ADPKD, liver parenchyma volume decreased from 1506 ± 431 to 1432 ± 403 ml during octreotide treatment.
In plain wordsIn patients with ADPKD, liver tissue volume decreased during octreotide treatment compared with baseline.
Peptide
Octreotide
Outcome
DecreaseLiver parenchyma volume
Study
n = 12
Comparator
baseline
Analysis
Secondary
Outcome group
Liver fat and liver function · Liver
Studied dose
40 mg every 28 days · 6 monthsAs given in this study (human).
Measurements
Liver parenchyma volume before octreotide
1506 ml
mean; +/- 431
Liver parenchyma volume on octreotide
1432 ml
mean; +/- 403
Source sentences
Summary
Octreotide-induced liver volume reduction was fully explained by a reduction in parenchyma volume from 1506 +/- 431 ml to 1432 +/- 403 ml.
2 context sentences(design, population, supporting numbers)
Summary · context
In a prospective, randomized, double-blind, crossover study, 6 months of octreotide (40 mg every 28 days) therapy limited kidney volume growth more effectively than placebo in 12 patients with ADPKD.
Summary · context
In this secondary, post hoc analysis of the above study, octreotide-induced changes in liver volumes compared with placebo and the relationship between concomitant changes in liver and kidney volumes were evaluated.
Report a problemFND-2018559603
06HumanObservational studyOther
During octreotide treatment in ADPKD, liver and kidney volume changes correlated significantly, with r = 0.67.
In plain wordsIn patients with ADPKD receiving octreotide, liver volume changes were linked to kidney volume changes.
Peptide
Octreotide
Outcome
IncreaseLiver and kidney volume change correlation
Study
n = 12
Analysis
Secondary
Outcome group
Liver fat and liver function · Liver
Studied dose
40 mg every 28 days · 6 monthsAs given in this study (human).
Measurements
Correlation of liver and kidney volume changes
0.67 r
during octreotide treatment; not significant during placebo
Source sentences
Summary
Changes in liver volumes were significantly correlated with concomitant changes in kidney volumes (r = 0.67) during octreotide but not during placebo treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
In a prospective, randomized, double-blind, crossover study, 6 months of octreotide (40 mg every 28 days) therapy limited kidney volume growth more effectively than placebo in 12 patients with ADPKD.
Summary · context
In this secondary, post hoc analysis of the above study, octreotide-induced changes in liver volumes compared with placebo and the relationship between concomitant changes in liver and kidney volumes were evaluated.
Report a problemFND-2018559604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.